Panelists review a patient with DLBCL relapsing 8 months after frontline Pola-R-CHP following an initial complete response. With low symptom burden and favorable performance status, the debate centers on optimal second-line strategy, outpatient CAR T feasibility, caregiver limitations, and balancing treatment intensity with quality-of-life and employment considerations in an urban setting.
In this segment, Dr. Devarakonda invites the panel to reflect on how updated clinical guidelines are shaping first line treatment patterns in EGFR mutated metastatic non-small cell lung cancer.
Acalabrutinib/venetoclax may offer less toxicity compared with other therapies in chronic lymphocytic leukemia, said Nicole Lamanna, MD.
Faculty analyze a primary refractory, high-intermediate–risk DLBCL case with persistent PET-positive disease after frontline R-CHOP and symptomatic progression. Discussion focuses referral for second-line CAR T and how rural geography and distance from a CAR-T center influence logistics. Panelists weigh aggressive disease biology against access barriers and caregiver availability in determining next steps.
According to Sebnem Ece Eksi, PhD, sympathetic signals led to shifts in cancer-associated fibroblasts to a more inflammatory state.
Findings from a study published by Sebnem Ece Eksi, PhD, and coauthors found that sympathetic nerves affect cancer-associated fibroblasts in a way that remodels the tissue environment.
Teams from Roswell Park and New York City discuss advances in CAR T-cell therapy for large B-cell lymphoma. Team Roswell presents real-world data comparing second-line CAR T therapy with standard salvage chemotherapy and transplant approaches, highlighting improved event-free and overall survival outcomes with CAR T. Team NYC challenges the findings, raising questions about patient selection, treatment bias, and how real-world data should be interpreted alongside randomized clinical trial results.
Brian Henick, MD, discussed plans to investigate agents targeting ULBP2/5/6, antibody-drug conjugates, and other novel therapies in lung cancer research.
Education, REMS certification, and long-term management are key barriers to the widespread adoption of bispecific antibodies in the community setting.
Marc Lehrer Greenwald, MD, discussed a recent patient case he had with a 22-year-old woman who was diagnosed with colorectal cancer.
The rising incidence of colorectal cancer among younger populations may be due to environmental factors, according to Marc Greenwald, MD.
Panelists debate whether the treatment paradigm in relapsed/refractory LBCL has fundamentally shifted from salvage chemotherapy and autologous transplant toward novel immune-based strategies. The discussion centers on CAR T-cell therapy versus bispecific antibodies, examining differences in outcomes. Faculty explore how emerging data, sequencing considerations, and real-world constraints are redefining treatment decision-making.
Experts weigh EGFR lung cancer combo therapies, cautioning against cross-trial comparisons and prioritizing CNS efficacy for brain metastases.
Panelists debate how to select between axicabtagene ciloleucel and lisocabtagene maraleucel for patients with rapidly progressive second-line DLBCL. Key arguments examine differences in efficacy signals, vein-to-vein time, and toxicity profiles and how these factors influence urgency of treatment. Faculty explore how real-world experience, institutional infrastructure, and patient-specific risk factors and lifestyle shape optimal CAR T product selection.
Experts unpack new EGFR-mutant lung cancer first-line options, weighing survival, CNS control, and toxicity as combo regimens reshape practice.
Dr. Krina Patel reviews a real-world comparative analysis showing improved progression-free and overall survival with idecabtagene vicleucel versus teclistamab in triple-class–exposed relapsed or refractory multiple myeloma, and discusses its implications for treatment sequencing and individualized care.
According to Marwan G. Fakih, MD, neutropenia may be a biomarker of benefit for patients with metastatic colorectal cancer receiving trifluridine/tipiracil and bevacizumab.
Although older patients saw a greater rate of AE-related discontinuations, survival outcomes were similar between groups.
An updated analysis of the eNRGy trial showed that zenocutuzumab may provide meaningful benefit beyond initial disease progression.
Patients with metastatic colorectal cancer who desire better disease control are best served with trifluridine/tipiracil plus bevacizumab, according to Marwan G. Fakih, MD.
Panelists discuss how high-risk disease biology and recent bispecific therapy heighten the need for timely, individualized sequencing and rigorous safety planning around infections, cytopenias, and early monitoring.
Panelists discuss how recent bispecific exposure does not necessarily preclude CAR T, but timing, disease tempo, infection/immune assessments, and realistic scheduling expectations shape readiness and planning.
Diane Simeone, MD, explained that shifting diagnosis toward earlier stages could raise the pancreatic cancer survival rate from 13% to over 80% for certain patients.
The majority of patients experiencing recurrence of their MIBC within 6 months of study start had high concentrations of ctDNA at baseline.
Several differences arise between community oncology centers and institutional oncology centers regarding the tools available and requirements of patients with cancer.
An effective regimen that partly incorporates oral therapy may be favorable from a patient convenience perspective, said Sagar Lonial, MD, FACP, FASCO.
CAR T-cell therapies and T-cell engagers may produce an “exciting” benefit on the radiosensitization of prostate tumors.
The phase 2 study aimed to compare the safety of pembrolizumab and radiation with or without olaparib in this high-risk population.
Despite differences in treatment tolerance across different RCC subgroups, survival outcomes were similar in a retrospective study.
Sarah Poland, MD, discussed the divergence between the IMpassion130 and IMpassion131 trials and the critical role of confirmatory trials in oncology.
